Please assess the completion status of the following clinical trial:

Trial Title: A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily signed informed consent ;~* Patient with primary Sjögren's syndrome according to the European - American consensus group criteria.~* Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies~* ESSDAI score ≥ 5.~Exclusion Criteria:~* Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and other autoimmune diseases;~* Abnormal laboratory parameters need to be excluded, including but not limited to:~* Immunosuppressive agents were used within 4 weeks prior to randomization.;~* The use of hydroxychloroquine was allowed during the trial, and the pre-randomized drug regimen was stable for less than 12 weeks;~* Use of biological agents for targeted therapy in the first 6 months of randomization;~* Treatment of primary Sjogren's syndrome with traditional Chinese medicine and proprietary Chinese medicine within 4 weeks before randomization;~* The use of saliva-stimulating drugs within 7 days prior to randomization;~* Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of the randomized pre-medication scheme is less than 4 weeks;~* Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before randomization;~* Infection with herpes zoster or HIV and hepatitis C virus(HCV) antibody positive;~* Currently suffering from active hepatitis or severe liver lesions and history;~* Malignant tumor patients ;~* Combined with involvement of important organs or neuropathy;~* Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the shorter).~* Pregnant , lactating women and men or women who have birth plans during the research;~* Investigator considers candidates not appropriating for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RC18 240mg (Type: EXPERIMENTAL): None
- RC18 160 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).